Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
NCT06835387Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan, oxaliplatin, fluorouracil, folinic acid in small bowel adenocarcinoma (SBA). Started Jun 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT06835387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835387.